AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-45. (Canceled).

46. (Previously Presented) A method for treating a wound and/or improving wound healing comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a peptide derived from amino acid 12 to amino acid 40 of human lactoferrin to a patient in need thereof, wherein:

said peptide inhibits a pro-inflammatory cytokine;

said peptide comprises ²⁰Cys-Phe-X₁-X₂-X₃-X₄-X₅-X₆-X₇-Lys-Val-Arg³¹ (SEQ ID NO: 99), wherein X₁ is Gln or Ala; X₂ is Trp or Leu; X₃ is Gln, Lys, Orn, Ala, or Nle; X₄ is Arg, Lys, or Ala; X₅ is Asn, Orn, Ala, or Nle; X₆ is Met or Leu; and X₇ is Arg or Lys; and said peptide is selected from the group consisting of SEQ ID NOS: 2-5, 8, 31-37, 47, 49, 51, 63, 65, 67, 70, 72-74, 80-83, and 87-97.

47-48. (Canceled).

- 49. (Previously Presented) The method of claim 46, wherein said wound is related to posttraumatic tissue injury.
- 50. (Previously Presented) The method of claim 49, wherein said posttraumatic tissue injury is caused by surgery.
- 51. (Previously Presented) The method of claim 46, wherein said would is related to thermic injury.

- 52. (Previously Presented) The method of claim 46, wherein said wound is a result of a metabolic process due to reduced nutritional supply.
- 53. (Previously Presented) The method of claim 52, wherein said wound is a diabetic ulcer, a leg ulcer, a decubitus ulcer or a gastric ulcer.
- 54. (Previously Presented) The method of claim 46, wherein said wound is a result of exposure to a toxic compound.
- 55. (Previously Presented) The method of claim 46, wherein said pharmaceutical composition is locally administered.
- 56. (Previously Presented) The method of claim 46, wherein said pharmaceutical composition is systemically administered.
 - 57. (New) The method of claim 46, wherein:

said peptide is derived from amino acid 20 to amino acid 31 of human lactoferrin, and said peptide is selected from the group consisting of SEQ ID NOS: 70, 72-74, 80-83, and 87-97.